ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Spyre Therapeutics Inc

Spyre Therapeutics Inc (SYRE)

21,76
-1,16
( -5,06% )
Aktualisiert: 20:54:29

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
21,76
Gebot
21,75
Fragen
21,81
Volumen
315.759
21,61 Tagesbereich 23,30
20,07 52-Wochen-Bereich 47,97
Marktkapitalisierung
Handelsende
22,92
Handelsbeginn
23,04
Letzte Trade
27
@
21.8599
Letzter Handelszeitpunkt
20:54:28
Finanzvolumen
US$ 7.046.328
VWAP
22,3155
Durchschnittliches Volumen (3 Mio.)
548.106
Ausgegebene Aktien
51.431.220
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-3,29
Gewinn pro Aktie (EPS)
-6,59
Erlöse
886k
Nettogewinn
-338,79M

Über Spyre Therapeutics Inc

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodie... Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23). Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Spyre Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SYRE. The last closing price for Spyre Therapeutics was US$22,92. Over the last year, Spyre Therapeutics shares have traded in a share price range of US$ 20,07 to US$ 47,97.

Spyre Therapeutics currently has 51.431.220 shares in issue. The market capitalisation of Spyre Therapeutics is US$1,18 billion. Spyre Therapeutics has a price to earnings ratio (PE ratio) of -3.29.

SYRE Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.59-2.6398210290822.3523.7521.1360810622.622699CS
40.763.619047619052124.8320.2559945022.52082915CS
12-6.18-22.118826055827.9429.0620.2554810623.63981262CS
26-4.27-16.404149058826.0340.2620.2555690227.29863581CS
52-1.61-6.889174154923.3747.9720.0753672129.37610659CS
15610.95101.29509713210.8147.9710.4248576028.7124388CS
26010.95101.29509713210.8147.9710.4248576028.7124388CS

SYRE - Frequently Asked Questions (FAQ)

What is the current Spyre Therapeutics share price?
The current share price of Spyre Therapeutics is US$ 21,76
How many Spyre Therapeutics shares are in issue?
Spyre Therapeutics has 51.431.220 shares in issue
What is the market cap of Spyre Therapeutics?
The market capitalisation of Spyre Therapeutics is USD 1,18B
What is the 1 year trading range for Spyre Therapeutics share price?
Spyre Therapeutics has traded in the range of US$ 20,07 to US$ 47,97 during the past year
What is the PE ratio of Spyre Therapeutics?
The price to earnings ratio of Spyre Therapeutics is -3,29
What is the cash to sales ratio of Spyre Therapeutics?
The cash to sales ratio of Spyre Therapeutics is 1,26k
What is the reporting currency for Spyre Therapeutics?
Spyre Therapeutics reports financial results in USD
What is the latest annual turnover for Spyre Therapeutics?
The latest annual turnover of Spyre Therapeutics is USD 886k
What is the latest annual profit for Spyre Therapeutics?
The latest annual profit of Spyre Therapeutics is USD -338,79M
What is the registered address of Spyre Therapeutics?
The registered address for Spyre Therapeutics is 1521 CONCORD PIKE, SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19803
What is the Spyre Therapeutics website address?
The website address for Spyre Therapeutics is www.spyre.com
Which industry sector does Spyre Therapeutics operate in?
Spyre Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
STAIScanTech AI Systems Inc
US$ 3,646
(77,85%)
132,46M
EFOIEnergy Focus Inc
US$ 2,212
(71,47%)
45,92M
KWEKWESST Micro Systems Inc
US$ 0,74
(58,46%)
227,12M
ADTXAditxt Inc
US$ 0,1066
(52,29%)
665,61M
CGBSCrown LNG Holdings Ltd
US$ 0,4313
(48,42%)
70,43M
INLFINLIF Limited
US$ 3,5701
(-78,14%)
10,72M
BPTHBio Path Holdings Inc
US$ 0,2116
(-66,58%)
5,35M
PTPIPetros Pharmaceuticals Inc
US$ 0,1282
(-56,25%)
24,15M
SEPNSepterna Inc
US$ 5,89
(-54,55%)
5,73M
RSLSReShape Lifesciences Inc
US$ 1,08
(-53,65%)
4,83M
ADTXAditxt Inc
US$ 0,1066
(52,29%)
663,6M
KWEKWESST Micro Systems Inc
US$ 0,74
(58,46%)
226,91M
PRPHProPhase Labs Inc
US$ 0,4386
(34,95%)
169,99M
INTCIntel Corporation
US$ 26,6808
(13,05%)
163,43M
STAIScanTech AI Systems Inc
US$ 3,646
(77,85%)
132,27M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock